Department of Infectious Diseases, Zhongnan Hospital, Wuhan University, Wuhan, China.
Eur J Clin Invest. 2020 Nov;50(11):e13412. doi: 10.1111/eci.13412. Epub 2020 Oct 2.
COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited.
In this retrospective study, epidemiological, clinical, laboratory, treatment and outcomes data of hospitalized patients with severe COVID-19 in Zhongnan Hospital of Wuhan University from January 1 to 7 March 2020, were collected. Binary logistic regression model was used to analyse risk factors for disease progression from severe COVID-19 illness to critical illness. The effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 disease were evaluated.
The results of the multivariate analysis from 175 patients with severe COVID-19 indicate that the use of methylprednisolone was a protective factor against disease progression from severe to critical illness(P < .001; OR: 0.054 95% CI: 0.017-0.173). Among patients with severe COVID-19 aged < 65 years, both the proportion of patients who progressed to critical illness (42.2% vs 90.0%, P = .000) and the mortality(6.7% vs 30.0%, P = .002) were lower for patients in methylprednisolone group, compared with those in the non-methylprednisolone group, whereas no statistical differences between the methylprednisolone group and the non-methylprednisolone group were found among patients with COVID-19 older than 65 years. Moreover, both the levels of CD4 T lymphocyte counts (646 vs 463/µL, P = .007) and IL-6 (241.9 vs 82.8 pg/mL, P = .025) were higher among patients with severe COVID-19 aged < 65 years, compared with those patients ≥ 65 years old.
Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness.
COVID-19 是一种在全球范围内传播并严重影响全球经济的公共卫生紧急事件。关于甲基强的松龙治疗重症 COVID-19 患者的疗效和安全性的数据仍然有限。
本回顾性研究收集了 2020 年 1 月 1 日至 3 月 7 日期间武汉大学中南医院收治的 175 例重症 COVID-19 住院患者的流行病学、临床、实验室、治疗和结局数据。采用二元逻辑回归模型分析从重症 COVID-19 进展为危重症的疾病进展风险因素。评估甲基强的松龙治疗重症 COVID-19 患者的疗效和安全性。
对 175 例重症 COVID-19 患者的多变量分析结果表明,使用甲基强的松龙是从重症向危重症进展的保护因素(P<0.001;OR:0.054,95%CI:0.017-0.173)。在年龄<65 岁的重症 COVID-19 患者中,与非甲基强的松龙组相比,甲基强的松龙组进展为危重症的患者比例(42.2% vs 90.0%,P=0.000)和死亡率(6.7% vs 30.0%,P=0.002)均较低,而在年龄>65 岁的 COVID-19 患者中,甲基强的松龙组与非甲基强的松龙组之间无统计学差异。此外,年龄<65 岁的重症 COVID-19 患者的 CD4 T 淋巴细胞计数(646 与 463/µL,P=0.007)和白细胞介素-6(241.9 与 82.8 pg/mL,P=0.025)水平均高于年龄>65 岁的患者。
来自有限样本的数据表明,对于年龄<65 岁的重症 COVID-19 患者,早期使用低或中剂量甲基强的松龙有积极作用,过度的免疫反应和细胞因子风暴可能是其疗效的部分原因。